SCHEMBL2932004

SCHEMBL2932004

CCOC(=O)c1nc2sc(C)c(C)n2c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
CYP1A2 P05177 2/20 0.46
GAA P10253 3/20 0.44
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
MAPK1 P28482 1/20 0.39
FHIT P49789 1/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 1/20 0.39
RAB9A P51151 1/20 0.39
TP53 P04637 1/20 0.38
ALOX12 P18054 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALOX15 P16050 1/20 0.38
ELANE P08246 1/20 0.38
POLB P06746 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1340250 0.79 MAPK1 (0.51) ALDH1A1CYP1A2GAAKMT2AMAPK1
SCHEMBL1398854 0.78 PTGS2 (0.37) ALDH1A1KMT2AMEN1MAPTHPGD
SCHEMBL1338507 0.75 ALDH1A1 (0.46) ALDH1A1CYP1A2KMT2AMEN1MAPK1
SCHEMBL11471960 0.75 ALDH1A1 (0.46) ALDH1A1CYP1A2GAAKMT2AMEN1
SCHEMBL2929906 0.72 ALDH1A1 (0.44) ALDH1A1CYP1A2GAAMAPK1MAPT
SCHEMBL2931389 0.72 IDO1 (0.52) ALDH1A1GAAKMT2AMEN1MAPK1
SCHEMBL17620710 0.71 ALDH1A1 (0.36) ALDH1A1CYP1A2GAAKMT2AMEN1
SCHEMBL2616832 0.70 GAA (0.58) ALDH1A1CYP1A2GAAKMT2AMEN1
SCHEMBL1339451 0.70 MAPK1 (0.67) ALDH1A1CYP1A2KMT2AMEN1MAPK1
SCHEMBL299269 0.69 GAA (0.56) ALDH1A1CYP1A2GAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079690-B1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-09-15 EP disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed
EP-2079690-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-07-22 EP disclosed
WO-2008038251-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 ALDH1A1 702/4885CYP1A2 558/4885GAA 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.